Page 1509 - Williams Hematology ( PDFDrive )

1484 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1485

644. Horn M, Glauche I, Muller MC, et al: Model-based decision rules reduce the risk of 671. Jabbour E, Cortes J, Santos FP, et al: Results of allogeneic hematopoietic stem cell
molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic mye- transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase
loid leukemia. Blood 121:378, 2013. inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117:3641,
645. Legros L, Rousselot P, Giraudier S, et al: Second attempt to discontinue imatinib 2011.
in CP-CML patients with a second sustained complete molecular response. Blood 672. Velev N, Cortes J, Champlin R, et al: Stem cell transplantation for patients with
120:1959, 2012. chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ALB
646. Graham SM, Jørgensen HG, Allan E, et al: Primitive, quiescent, Philadelphia-positive kinase domain mutation T315I. Cancer 116:3631, 1010.
stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in 673. Nicolini FE, Basak GW, Soverini S, et al: Allogeneic stem cell transplantation for
vitro. Blood 99:319, 2002. patients harboring T315I BCR-ABL mutated leukemias. Blood 118:5697, 2011.
647. Russo D, Martinelli G, Malagola M, et al: Effects and outcome of a policy of inter- 674. Goldman J: Implications of imatinib mesylate for hematopoietic stem cell transplan-
mittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood tation. Semin Hematol 38:28, 2001.
121:5138, 2013. 675. Barrett J: Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin
648. CML Autograft Trials Collaboration: Autologous stem cell transplantation in chronic Hematol 40:59, 2003.
myeloid leukaemia: A meta-analysis of six randomized trials. Cancer Treat Rev 33:39, 676. Messner HA, Curtis JE, Lipton JL, et al: Three decades of allogeneic bone marrow
2007. transplants at the Princess Margaret Hospital. Clin Transplant 289, 1999.
649. Goldman J: Autologous stem-cell transplantation for chronic myelogenous leukemia. 677. Byrne JL, Stainer C, Hyde H, et al: Low incidence of acute graft-versus-host disease
Semin Hematol 30:53, 1993. and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell
650. Talpaz M, Kantarjian H, Liang J, et al: Percentage of Philadelphia chromosome transplantation from sibling donors with methotrexate and dose-monitored cyclospo-
(Ph)-negative and Ph-positive cells found after autologous transplantation for chronic rin A prophylaxis. Bone Marrow Transplant 22:541, 1988.
myelogenous leukemia depends on percentage of diploid cells induced by conven- 678. Goldman J, Apperley J, Kanfer E, et al: Imatinib or transplant for chronic myeloid
tional dose chemotherapy before collection of autologous cells. Blood 85:3257, leukemia? Lancet 362:172, 2003.
1995. 679. Van Rhee F, Szydlo RM, Hermans J, et al: Long-term results after allogeneic bone
651. Drummond MW, Marin D, Clark RE, et al: Mobilization of Ph chromosome-nega- marrow transplantation for chronic myelogenous leukemia in chronic phase: A report
tive peripheral blood stem cells in chronic myeloid leukemia patients with imatinib from the Chronic Leukemia Working Party of the European Groups for Blood and
mesylate-induced complete cytogenetic remission. Br J Haematol 123:479, 2003. Marrow Transplantation. Bone Marrow Transplant 20:553, 1997.
652. Hui CH, Goh KY, White D, et al: Successful peripheral blood stem cell mobilisation 680. Weisdorf DJ, Anasetti C, Antin JH, et al: Allogeneic bone marrow transplantation for
with filgrastim in patients with chronic myeloid leukaemia achieving complete cyto- chronic myelogenous leukemia: Comparative analysis of unrelated versus matched
genetic response with imatinib, without increasing disease burden as measured by sibling donor transplantation. Blood 99:1971, 2002.
quantitative real-time PCR. Leukemia 17:821, 2003. 681. Laporte JP, Gorin NC, Rubinstein P, et al: Cord-blood transplantation from an unrelated
653. Kreuzer KA, Kluhs C, Baskaynak G, et al: Filgrastim-induced stem cell mobilization donor in an adult with chronic myelogenous leukemia. N Engl J Med 335:167, 1997.
in chronic myeloid leukaemia patients during imatinib therapy: Safety, feasibility and 682. Oehler VG, Gooley T, Snyder DS, et al: The effects of imatinib mesylate treatment
evidence for an efficient in vivo purging. Br J Haematol 124:195, 2004. before allogeneic transplantation for chronic myeloid leukemia. Blood 109:1782, 2007.
654. Gordon MK, Sher D, Karrison T, et al: Successful autologous stem cell collection in 683. Weisser M, Schmid C, Schoch C, et al: Resistance to pretransplant imatinib therapy
patients with chronic myeloid leukemia in complete cytogenetic response, with quan- may adversely affect the outcome of allogeneic stem cell transplantation in CML. Bone
titative measurement of BCR-ABL expression in blood, marrow, and apheresis prod- Marrow Transplant 36:1017, 2005.
ucts. Leuk Lymphoma 49:531, 2008. 684. Jabbour E, Cortes J, Kantarjian H, et al: Novel tyrosine kinase inhibitor therapy before
655. Olavarria E: Autologous stem cell transplantation in chronic myeloid leukemia. Semin allogeneic stem cell transplantation in patients with chronic myeloid leukemia: No
Hematol 44:252, 2007. evidence for increased transplant-related toxicity. Cancer 110:340, 2007.
656. Perseghin P, Gambacorti-Passerini C, Tornaghi L, et al: Peripheral blood progeni- 685. Radich JP, Gehly G, Gooley T, et al: Polymerase chain reaction detection of the BCR-
tor cell collection in chronic myeloid leukemia patients with complete cytogenetic ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid
response after treatment with imatinib mesylate. Transfusion 45:1214, 2005. leukemia: Results and implications in 346 patients. Blood 85:2632, 1995.
657. Cervantes F, Hernandez-Boluda JC, Odriozola J, et al: Imatinib mesylate (STI571) 686. Goldman JM: Therapeutic strategies for chronic myeloid leukemia in chronic (stable)
treatment in patients with chronic-phase chronic myelogenous leukaemia previ- phase. Semin Hematol 40:10, 2003.
ously submitted to autologous stem cell transplantation. Br J Haematol 120:500, 687. Miller JS, Cooley S, Parham P, et al: Missing KIR ligands are associated with less
2003. relapse and increased graft-versus-host disease (GVHD) following unrelated donor
658. Simon W, Segel GB, Lichtman MA: Early allogeneic stem cell transplantation for allogeneic HCT. Blood 109:5058, 2007.
chronic myelogenous leukemia in the imatinib era: A preliminary assessment. Blood 688. Elmaagacli AH, Ottinger H, Koldehoff M, et al: Reduced risk for molecular disease in
Cells Mol Dis 37:116, 2006. patients with chronic myeloid leukemia after transplantation from a KIR-mismatched
659. Goldman J: Allogeneic stem cell transplantation for chronic myeloid leukemia— donor. Transplantation 79:1741, 2005.
Status in 2007. Bone Marrow Transplant 42:S11, 2008. 689. Nadal E, Garin M, Kaeda J, et al: Increased frequencies of CD4(+)CD25(high) T(regs)
660. Giralt SA, Arora M, Goldman JM, et al: Chronic Leukemia Working Committee, correlate with disease relapse after allogeneic stem cell transplantation for chronic
Center for International Blood and Marrow Transplant Research: Impact of imatinib myeloid leukemia. Leukemia 21:472, 2007.
therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the 690. Crawley C, Szydlo R, Lalancette M, et al: Outcomes of reduced-intensity transplanta-
treatment of chronic myeloid leukaemia. Br J Haematol 137:461, 2007. tion for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic
661. Maziarz RT: Who with chronic myelogenous leukemia to transplant in the era of Leukemia Working Party of the EBMT. Blood 106:2969, 2005.
tyrosine kinase inhibitors? Curr Opin Hematol 15:127, 2008. 691. Kebriaei P, Detry MA, Giralt S: Long-term follow-up of allogeneic hematopoietic
662. Hehlmann R, Berger U, Pfirrmann M, et al: Drug treatment is superior to allografting stem-cell transplantation with reduced-intensity conditioning for patients with
as first-line therapy in chronic myeloid leukemia. Blood 109:4686, 2007. chronic myeloid leukemia. Blood 110:3456, 2007.
663. Thomas ED, Clift RA, Fefer A, et al: Marrow transplantation for the treatment of 692. Uzunel M, Mattsson J, Brune M, et al: Kinetics of minimal residual disease and chime-
chronic myelogenous leukemia. Ann Intern Med 104:155, 1986. rism in patients with chronic myeloid leukemia after nonmyeloablative conditioning
664. Apperley JF: Hematopoietic stem cell transplantation in chronic myeloid leukemia. and allogeneic stem cell transplantation. Blood 101:469, 2003.
Curr Opin Hematol 5:445, 1998. 693. Or R, Shapira MY, Resnick I, et al: Nonmyeloablative allogeneic stem cell transplan-
665. Cooperative Study Group on Chromosomes in Transplanted Patients: Cytogenetic tation for the treatment of chronic myeloid leukemia in first chronic phase. Blood
follow-up of 100 patients submitted to bone marrow transplantation for Philadelphia 101:441, 2003.
chromosome-positive chronic myeloid leukemia. Eur J Haematol 40:50, 1988. 694. Bornhauser M, Kiehl M, Siegert W, et al: Dose-reduced conditioning for allografting
666. McGlave P, Bartoch G, Anasetti C, et al: Unrelated donor marrow transplantation in 44 patients with chronic myeloid leukaemia: A retrospective analysis. Br J Haematol
therapy for chronic myelogenous leukemia. Blood 81:543, 1993. 115:119, 2001.
667. Fernandez HF, Tran HT, Albrecht F, et al: Evaluation of safety and pharmacokinetics 695. Das M, Saikia TK, Advani SH, et al: Use of a reduced-intensity conditioning regi-
of administering intravenous busulfan in a twice-daily or daily schedule to patients men for allogeneic transplantation in patients with chronic myeloid leukemia. Bone
with advanced hematologic malignant disease undergoing stem cell transplantation. Marrow Transplant 32:125, 2003.
Biol Blood Marrow Transplant 8:486, 2002. 696. Feinstein L, Storb R: Reducing transplant toxicity. Curr Opin Hematol 8:342, 2001.
668. Radich JP, Gooley T, Bensinger W, et al: HLA-matched related hematopoietic cell 697. Koh LP, Hwang WY, Chuah CT, et al: Imatinib mesylate (STI-571) given concurrently
transplantation for chronic-phase CML using a targeted busulfan and cyclophos- with nonmyeloablative stem cell transplantation did not compromise engraftment
phamide preparative regimen. Blood 102:31, 2003. and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in
669. Warlick E, Ahn KW, Pedersen TL, et al: Reduced intensity conditioning is superior blast crisis. Bone Marrow Transplant 31:305, 2003.
to nonmyeloablative conditioning for older chronic myelogenous leukemia patients 698. McCann SR: Molecular response to imatinib mesylate following relapse after alloge-
undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. neic SCT for CML. Blood 101:1200, 2003.
Blood 119:4083, 2012. 699. Vandenberghe P, Boeckx N, Ronsyn E, et al: Imatinib mesylate induces durable com-
670. Radich J: Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin plete remission of advanced CML persisting after allogeneic bone marrow transplan-
Hematol 47:354, 2010. tation. Leukemia 17:458, 2003.

Kaushansky_chapter 89_p1437-1490.indd 1484 9/18/15 3:42 PM